Autopsy report · NCT04556617
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cause of deathFunding or business
“study terminated due to business realignment”
Life of this trial
- Ran for about 1 year 8 months before it stopped.
- 19 participants enrolled.
- Results were posted on the registry 2 years 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Opna Bio LLC
- Sponsor type
- Industry
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- PLX2853 20 mg; Olaparib; Abiraterone acetate; Prednisone; PLX2853 40 mg; PLX2853 80 mg
- Participants
- 19
- Sites
- 8
- Countries
- United Kingdom, United States
Trials that died the same way
- A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
“Study terminated due to business priorities” - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
“Study terminated for business reasons” - Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
“Study terminated due to business decision” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
“Study terminated for strategic business reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.